Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Romanelli

Showing results (281-290 of 310) with videos related to

Pageof 31
Sort By:
Dermatology and Therapy|September 24, 2024
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World EvidencePiergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
International Angiology : a Journal of the International Union of Angiology|February 11, 2026
Multi-specialty recommendations for the appropriate and affordable lower limb vein-lymphatic disorders managementSergio Gianesini, Massimo Danese, Maurizio Pagano, et al.
The Journal of Dermatology|April 16, 2025
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort StudyGianluca Avallone, Carlo Alberto Maronese, Martina Zussino, et al.
Acta Dermato-Venereologica|October 28, 2020
Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with PsoriasisCéline Phan, Nathalie Beneton, Juliette Delaunay, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Acta Dermato-Venereologica|April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitisLuca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Medicina (Kaunas, Lithuania)|February 26, 2025
High-Frequency and Ultra-High-Frequency Ultrasound in Dermatologic Diseases and Aesthetic MedicineGiulio Argalia, Alfonso Reginelli, Elisa Molinelli, et al.
Pageof 31

Showing results (281-290 of 310) with videos related to

Sort By:
Pageof 31
Dermatology and Therapy|September 24, 2024
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World EvidencePiergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, et al.
Dermatology and Therapy|February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
International Angiology : a Journal of the International Union of Angiology|February 11, 2026
Multi-specialty recommendations for the appropriate and affordable lower limb vein-lymphatic disorders managementSergio Gianesini, Massimo Danese, Maurizio Pagano, et al.
The Journal of Dermatology|April 16, 2025
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort StudyGianluca Avallone, Carlo Alberto Maronese, Martina Zussino, et al.
Acta Dermato-Venereologica|October 28, 2020
Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with PsoriasisCéline Phan, Nathalie Beneton, Juliette Delaunay, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Acta Dermato-Venereologica|April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitisLuca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Medicina (Kaunas, Lithuania)|February 26, 2025
High-Frequency and Ultra-High-Frequency Ultrasound in Dermatologic Diseases and Aesthetic MedicineGiulio Argalia, Alfonso Reginelli, Elisa Molinelli, et al.
Pageof 31